Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Manufacturing Issue Results in "Complete Response" Letter For Warner Chilcott Contraceptive

This article was originally published in The Pink Sheet Daily

Executive Summary

Warner Chilcott hopes to receive FDA approval for the low-dose product within six months.

You may also be interested in...



Actonel Delayed-Release Back On Track With New PDUFA Date In October

Three-month extension clarifies regulatory outlook for Warner Chilcott's once-weekly successor to osteoporosis blockbuster Actonel.

Actonel Delayed-Release Back On Track With New PDUFA Date In October

Three-month extension clarifies regulatory outlook for Warner Chilcott's once-weekly successor to osteoporosis blockbuster Actonel.

Warner Chilcott Transformation Underway With Integration Of P&G's Pharma Biz

With the acquisition of Procter & Gamble's pharma business complete, the specialty drug maker adds 1,900 employees.

Topics

UsernamePublicRestriction

Register

PS142351

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel